



Canadian Society of Transplantation Société canadienne de transplantation

# 2011 ANNUAL SCIENTIFIC MEETING

## **FINAL PROGRAM**

RÉUNION SCIENTIFIQUE ANNUELLE 2011

# **PROGRAMME FINAL**

Fairmont Tremblant
Mont-Tremblant, Québec

March 2-5, 2011 du 2 au 5 mars 2011







# CANADIAN SOCIETY OF TRANSPLANTATION SOCIÉTÉ CANADIENNE DE TRANSPLANTATION

FINAL PROGRAM-PROGRAMME FINAL- du 2 au 5 mars-March 2 to 5, 2011

	FINAL PROGRAM-PROGRAMME FINAL— du 2 au 5 mars-March 2 to 5, 2011							
WEDNESDAY, MARCH 2 / LE MERCREDI 2 MARS 2011								
0700-1800	CST/AST Distinguished Fellows Research Symposium - Mali I & II							
1200-1800	CST Board Meeting (closed) - Soutana III							
1200-1800	REGISTRATION – INSCRIPTION - Foyer							
1800-2200	CST Pediatric Group Meeting - Soutana I & II							
	1800-1900 Buffet Dinner (CST Pediatric Group Members Only)							
	1900-2030 Pediatric Ethics Symposium (All Welcome): Case based presentation and discussion around challenging ethical issues in pediatric solid organ transplantation. 2030-2130 CST Pediatric Group Annual Business Meeting (Closed)							
1800-1830	CST/AST Distinguished Fellows Research Symposium - Awards Reception - Mali I & II							
1900-2100	DINNER SYMPOSIUM (All are welcome) - Mali III & IV							
	Chair: Marie-Josée Hébert  Objectives: Review the most recent evidence related to prevalence and the risk of post-transplant malignancies.  Evaluate the role of immune-suppression in malignancy and the potential impact of m-TOR-inhibition on malignancy risk. Share clinical management perspectives for post-transplant risk factors associated with malignancy.  Post-transplant Malignancy: Perspectives on Risk and Management							
	The Risk for Post-Transplant Malignancy - Dr. Edward Geissler (Germany)  New Strategies to Manage Post-Transplant Malignancy Risk - Dr. Graeme Russ (Australia)							
	THURSDAY, MARCH 3 / LE JEUDI 3 MARS 2011							
0700-1700	REGISTRATION - INSCRIPTION - Foyer							
0700-0800	SUNRISE SYMPOSIUM - Mali III & IV Chair: Don Vinh Antivirals - The Next Generation CMV - Atul Humar (Edmonton, AB) Objectives: Review current antiviral therapy for CMV. Review issues around resistance. Review the next generation antiviral agents for CMV. Therapeutic Strategies for Polyomavirus BK - Empiricism vs Rational Design - Parmjeet Randhawa (Pittsburgh, PA) Objectives: To summarize current treatment modalities for polyoma BK infection. To highlight current trends in drug development for BK virus. Next Generation Diagnostics - Deepali Kumar (Edmonton, AB) Objectives: To learn principles of CMV immunologic assays. To learn the current knowledge of where T cell assays can be applied. To learn where future research is needed before routine use of assays.							
	Antivirals - The Next Generation CMV - Atul Humar (Edmonton, AB) Objectives: Review current antiviral therapy for CMV. Review issues around resistance. Review the next generation antiviral agents for CMV. Therapeutic Strategies for Polyomavirus BK - Empiricism vs Rational Design - Parmjeet Randhawa (Pittsburgh, PA) Objectives: To summarize current treatment modalities for polyoma BK infection. To highlight current trends in drug development for BK virus. Next Generation Diagnostics - Deepali Kumar (Edmonton, AB) Objectives: To learn principles of CMV immunologic assays. To learn the current knowledge of where T cell assays							
0815-1500	Antivirals - The Next Generation CMV - Atul Humar (Edmonton, AB) Objectives: Review current antiviral therapy for CMV. Review issues around resistance. Review the next generation antiviral agents for CMV. Therapeutic Strategies for Polyomavirus BK - Empiricism vs Rational Design - Parmjeet Randhawa (Pittsburgh, PA) Objectives: To summarize current treatment modalities for polyoma BK infection. To highlight current trends in drug development for BK virus. Next Generation Diagnostics - Deepali Kumar (Edmonton, AB) Objectives: To learn principles of CMV immunologic assays. To learn the current knowledge of where T cell assays can be applied. To learn where future research is needed before routine use of assays.  CST SPECIAL INTEREST GROUP MEETINGS							
0815-1500	Antivirals - The Next Generation CMV - Atul Humar (Edmonton, AB) Objectives: Review current antiviral therapy for CMV. Review issues around resistance. Review the next generation antiviral agents for CMV. Therapeutic Strategies for Polyomavirus BK - Empiricism vs Rational Design - Parmjeet Randhawa (Pittsburgh, PA) Objectives: To summarize current treatment modalities for polyoma BK infection. To highlight current trends in drug development for BK virus. Next Generation Diagnostics - Deepali Kumar (Edmonton, AB) Objectives: To learn principles of CMV immunologic assays. To learn the current knowledge of where T cell assays can be applied. To learn where future research is needed before routine use of assays.							

**1215-1315** *Luncheon - Foyer* 

CST PLENARY I -IDENTIFYING RISKS THROUGHOUT THE TRANSPLANT CONTINUUM - Mali 111 & IV Chairs: Steven Paraskevas and Marcelo Cantarovich 1600-1605 **Welcome Remarks** Marcelo Cantarovich, CST President 1605-1630 Linking Innate and Adaptive Immunity - Dr. Richard Flavell (New Haven, CT) ANDREW LAZAROVITS LECTURER Objectives: Concepts of innate and adaptive immunity. The role of innate sensors in activating adaptive immunity. Role of NLR in innate and adaptive immunity. 1630-1700 Starting From Zero-The Value of Time-Zero Allograft Biopsies – Michael Mengel (Edmonton, AB) Objectives: To give an update regarding the clinical value of time-zero biopsies. To present new molecule insights into time-zero biopsies. To critically discuss the value of time-zero biopsies. Genomic Profiles of Post-Transplant Risks - Philip Halloran (Edmonton, AB)) 1700-1730 1730-1800 Tolerance Assays - Ready For Clinical Use? - Kenneth Newell (Atlanta, GA) Objectives: To be familiar with assays used to assess immune tolerance. To distinguish between biomarkers liver and kidney tolerance. To appreciate the potential role of B cells in tolerance. 1800-1930 CST - ANNUAL GENERAL MEETING - Mali 111 & 1V 1930-2000 RECEPTION amongst the Exhibitors-Exhibits open - Mali | & || 2000-0N **SOCIAL EVENING -** Centre des Congrès Dinner with entertainment by THE MARGINAL DONORS BAND FRIDAY, MARCH 4 / LE VENDREDI 4 MARS 2011 0645-1200 **REGISTRATION – INSCRIPTION** - Foyer 0700-0745 SUNRISE SYMPOSIUM - Mali III & IV Chair: John Gill **Keeping North America Competitive in Clinical Trials** Perspective of Canada's Leadership in Clinical Trials - Philip Halloran (Edmonton, AB) Perspective of the Pharmaceutical Industry in Development of Innovative Medicines - Nancy Krieger (East Hanover, NJ) How Can We Ensure Canadian and North American Prominence in International Clinical Trials? - John Gill (Vancouver, BC) and Robert Gaston (Birmingham, AB) 0700 - ON SET-UP POSTERS (odd numbers) - Kamichat/Sasseville/Joseph 0700-ON **EXHIBITS CONTINUE - Mali 1 & 11** 0800-0930 SPECIAL CST-CSI JOINT SESSION- Funding Transplantation Research in Canada - Mali III & IV 0800-0805 Introductions - Tony Jevnikar (London, ON) Transplantation Funding at CIHR - Marc Quellette, Scientific Director, Institute of 0805-0845 Infection and Immunity, CIHR and Lori West, Interim Scientific Director, Institute of Circulatory and Respiratory Health, CIHR 0845-0930 Panel Discussion - Lee Anne Tibbles, Marianna Newkirk, Peter Nickerson, Mike Ratcliffe, Marc Ouellette, Lori West, Joaquim Madrenas. Objectives: Update current and future research opportunities in transplantation. Understand who is disadvantaged by only provincial organ allocation. Review mechanisms to create solutions for patients. Discuss barriers to implementing solutions. 0930-1200 **CST CONCURRENT SESSIONS** 

1600-1800

LUNG - Soutana II

KIDNEY/PANCREAS - Mali III & IV

HEART - Soutana III LIVER - Soutana I

**DONATION - Outardes** 

DONATION -	Outardes						
		CONCURRENT LUNG - Soutana II					
	Chair: N	Marc de Perrot					
0930-1000	Expanding The Lung Donor Pool Through Gene Therapy - Shaf Keshavjee (Toronto, ON)						
1000-1030	Nutrition Break-Pause Santé						
1030-1130	Abstract Presentations						
	1030	Airway Pressure and Compliance in the Evaluation of Donor Lung Injury During Protective Ex Vivo Lung Perfusion in a Porcine Brain Death Model - Jonathan Yeung - (Toronto, ON) (Abstract # 490)					
	1040	Lung Progenitor Cell Profiles in Bronchiolitis Obliterans Syndrome are Mediated by Circulating Inflammatory and Stem Cell-Specific Factors - Sarah Gilpin <i>(Toronto, ON)</i> (Abstract # 469)					
	1050	Long Term Immune Responses to pandemic H1N1 Infection in Transplant Recipients - Aliyah Baluch <i>(Edmonton, AB)</i> (Abstract # 447)					
	1100	Assessing Health-related Quality of Life in Lung Transplant Recipients using the Health Utility Index (HUI3) Measure - Maria Santana (Edmonton, AB) (Abstract # 442)					
	1110	Incorporating Measures of Health-Related Quality of Life (HRQL) into the Routine Clinical Care of Lung-Transplant Patients - Maria Santana (Edmonton, AB) (Abstract # 443)					
	1120	A Survey of Strategies for Safe Living Among Lung Transplant Recipients - Avni Jain (Edmonton, AB) (Abstract # 453)					
1130-1200	Update	Update in Lung Transplantation for Cystic Fibrosis - Liz Tullis (Toronto, ON)					
		KIDNEY/PANCREAS - Mali III & IV					
0930-1000	Chairs: Ian Alwayn & Tammy Keough-Ryan  Islet Transplantation - Reaching New Heights - Jose Oberholzer (Chicago, IL)  Objectives: To understand the principals of islet transplantation. To discuss current outcomes in islet transplantation. To review limitations of islet transplantation.						
1000-1030	Nutriti	Nutrition Break-Pause Santé					
1030-1130	Abstra	cts Presentations					
	1030	Successful Tolerance Induction with a Post KidneyTransplantation (Tx) Regimen of Total Lymphoid Irradiation (TLI), Antithymocyte Globulin (ATG) and Donor Purified CD34 Progenitor Cells in HLA-Matched Recipients - Stephan Busque ( <i>Palo Alto, CA</i> ) (Abstract #415)					
	1040	The Importance of PRA in HLA Identical Kidney Transplant Recipients - Peter Chang (Burnaby, BC) (Abstract # 436)					
	1050	Serum FGF-23 Levels Predict Mortality And Allograft Loss In Kidney Transplant					

- Serum FGF-23 Levels Predict Mortality And Allograft Loss In Kidney Transplant Recipients (Abstract #463) Circulating Angiopoietin-2 levels and mortality in kidney transplant recipients (Abstract #464) Istvan Mucsi (Montréal, QC)
- 1100 Evaluating The Relationship Between Post-Operative Serum Tacrolimus Concentrations Following Renal Transplantation And Delayed Graft Function: The DEGRAFTS Study. Paul Murgoi (Sherbrooke, QC) (Abstract # 451)
- 1110 Characterization of Regulatory and Effector T Cells in Renal Transplant Recipients after Induction with Thymoglobulin vs. Basiliximab: an Interim Report Sacha De Serres (Boston, MA) (Abstract # 433)
- Effect of recipient's KIR genes profile and their incompatibility with donor's HLA ligands on the outcome of human renal transplantation: Association with Inflammation and Tubulitis Noureddine Berka (Calgary, AB) (Abstract # 472)

## **ABO Incompatible Kidney Transplants - Ready for Prime Time? -** Jean Tchervenkov *(Montréal, QC)*

Objectives: Review results of ABO incompatible transplant around the world. Review best clinical protocol currently. Give basic perspective on basic science of ABO incompatible transplant.

#### **CONCURRENT HEART - Soutana III**

Chairs: Debra Isaac and Anne Dipchand

## **O930-1000** Indications and Outcomes of Cardiac Retransplantation – Maryl Johnson (Madison, WI)

Objectives: To become aware of outcomes following cardiac retransplantation. To understand predictors of outcome following cardiac transplantation. To be able to select appropriate candidates for cardiac retransplantation.

#### 1000-1030 Nutrition Break-Pause Santé

#### 1030-1130 Abstracts Presentations

- 1030 CD4 T Helper Cell Profiling In Heart Transplant Recipients: Comparison Between CNI-, Rapamycin- And Anti-CD25 Mab-Based Immunosuppression Syamala Kalyanasundaram (Montréal, QC) (Abstract # 502)
- Blebbistatin Attenuates Collagen Gel Contractility in Human Bone Marrow Derived Mesenchymal Stem Cells Melanie Ngo (Winnipeg, MB) (Abstract # 413)
- 1050 CD155 on Human Vascular Endothelial Cells Attenuates the Acquisition of Effector Functions in Activated CD8 T Cells Jonathan Choy (Burnaby, BC) (Abstract # 428)
- 1100 Mevalonate Depletion Impairs Survival of Primary Human Mesenchymal Stem Cells Through Depletion of NF-kB Darren Freed (Winnipeg, MB) (Abstract # 414)
- ABO-Incompatible Heart Transplantation In Children How Far Can We Go? A Multicenter Survey. Simon Urschel (Edmonton, AB) (Abstract # 449)
- 1120 Reduction Of Cold Ischemia-Reperfusion Injury By Graft-Expressing Clusterin In Heart Transplantation (Abstract # 470) Reduction of Cold Injury Of Donor Organs By Supplement Of Recombinant Clusterin Protein In Cold Preservation Solution (Abstract # 471) Caigan Du (Vancouver, BC)

## 1130-1200 Are NK Cells The Final Common Pathway Towards Cardiac Allograft Vasculopathy? - Joren Madsen (Boston, MA)

#### **CONCURRENT SESSION LIVER - Soutana I**

Chair: Eberhard Renner

## 0930-1000 Debate: Cold or Warm Liver Perfusion? –Markus Selzner (Toronto, ON) &

Roberto Hernandez-Alejandro (London, ON)

Objectives: Learn about mechanisms of preservation injury. Understand principles of perfured liver reperfusion. Learn about assessment and repair of marginal grafts.

#### 1000-1030 Nutrition Break-Pause Santé

#### 1030-1130 Abstracts Presentations

- The Utility Of An In-Tube Interferon Gamma Release Assay (Quantiferon-HCV) For Assessment Of The Severity Of Recurrent Hepatitis C After Liver Transplantation Sonal Asthana (Edmonton, AB) (Abstract # 521)
- Alpha-fetoprotein Gradient before Liver Transplantation as a Predictor of Post Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma (Abstract # 532) Total Tumor Volume and Alphafetoprotein >400 are Independent Predictors of Post Transplant Tumor Recurrence in Patients with Hepatocellular Carcinoma (Abstract # 533) Samy Kashkoush (Edmonton, AB)
- A Cell Penetrating Heme Oxygenase to Improve the Resistance of Steatotic Livers to Reperfusion Injury Following Transplantation Scott Livingston (Halifax, NS) (Abstract # 497)
- The Models for End-Stage Liver Disease Accurately Predict 90-Day Liver Transplant Wait-List Mortality in Atlantic Canada Paul Renfrew (Halifax, NS) (Abstract # 393)
- The Effect of Caval Anastomotic Techniques on Renal Function Post Liver Transplantation Saud Alzaid (Montréal, QC) (Abstract # 530)
- 1120 CD4 T Helper Cell Profiling In Liver Transplant Recipients: Comparison Between CNI-, Rapamycin- And Anti-CD25 Mab-Based Immunosuppression Syamala Kalyanasundaram (Montréal, QC) (Abstract # 503)

### 1130-1200 Genetic Variation in IL 28b and Predictor of HCV Recurrence after Transplantation - Marc Bilodeau (Montréal, QC)

## **CONCURRENT DONATION / ALLIED HEATH - Outardes**

Chairs: Dr. Greg and Ed Ferre

**O930-1045 Management of the Potential Organ Donor** - Kenneth Wood, *(Danville, PA) Objectives: Review the Physiology of brain death. Discuss a pathophysiologic strategy for cardiac/hemodynamic management.. Overview lung donor management.* 

	1045-1100	1100 Nutrition Break-Pause Santé				
	1100-1130	Abstracts Presentations				
	1100 1100	1030	Evaluation of an Advanced Practice Nurse Collaborative Chronic Kidney Care Model for Renal Transplant Patients - Janice Bissonnette (Ottawa, ON) (Abstract # 456)			
		1040	The Beanstalk Program: Developmentally Focused Care For The Young Transplant Child During Prolonged Hospitalization - Stephanie So (Toronto, ON) (Abstract # 444)			
		1050	Surfing for Health: The Development of a Transplant Website for Teens - Moira Korus (Toronto, ON) (Abstract # 425)			
		1100	Evidence For Excellent Adherence With Immunosuppressive Medications In Lung Transplant Recipients Utilizing A Centralized Dispensing Strategy - Nilu Partovia (Vancouver, BC) (Abstract # 409)			
		1110	World Transplant Games: Incentive to Improve Physical Fitness and Habitual Activity in Paediatric Solid Organ Transplant Recipients - Robin Deliva <i>(Toronto, ON)</i> (Abstract # 485)			
		1120	Body Image and Eating Attitudes and Behaviors among Adolescent Heart and Lung Transplant Recipients - Janet Evans <i>(Toronto, ON)</i> (Abstract # 506)			
	1130-1200	World	Transplant Games 2011 - Dave Smith, CTA			
1200-1600		acist Group Meeting (Open to all Delegates) - Sauteux-Corriveau ifer Harrison and Christopher Daley				
	1200-ON	Lunch -	Kirouac			
	1215-1255	- Christia	Infections in Solid Organ Transplant: Overview and Case Presentation on Coursol, BPharm, M.Sc, Clinical Pharmacist in Solid Organ Transplant, Royal-Hospital, McGill University Health Center			
	1255-1335	The ABCs of Pediatric Solid Organ Transplantation -Anita Babu, BScPhm, RPh, Pharmacist, Transplant Centre, Hospital for Sick Children  Optimizing Immunosuppressant Therapy Adherence in Solid Organ  Transplantation - Dr. Marie Chisholm, PharmD, MPH, FCCP, FASHP, Professor and Head, Department of Pharmacy Practice and Science, University of Arizona College of Pharmacy				
	1335-1420					
	1420-1500	BScPhari Transpla	mmunosuppressives: What is Hot? What is New? - Nilu Partovi, m, Pharm.D, FCSHP, Clinical Coordinator & Pharmacotherapeutic Specialist, nt/Immunology, Vancouver General Hospital, Clinical Professor, Faculty of eutical Sciences, University of British Columbia			
	1500-1600	Busines	s Meeting - (Pharmacist SIG Members Only)			
	1600	Close				
1200-1600	*****	**********************************				
1600-1800		CST PLENARY SESSION II - Frontiers in Immunosuppression - Mali III & IV Chair: John Gill				
	1600-1630	Getting Harbor,	g firm with Abs: Targeting B-Cell Pathways – Millie Samaniego <i>(Ann MI)</i>			
	1/00 1700	therapy	es: To understand the role of B-cells in alloimmunity. To review the principles of B-cell in transplantation. To discuss new B-cell agents in development.			
	1630-1700	Objective of the cl	Road, Jak: Update on Tasocitinib – Stephan Busque (Palo Alta, CA) es: Understand the mechanism of action of tasocitinib. Become familiar with the results inical evaluation of tasocitinib in kidney transplant recipients. Become aware of the risks ential benefits associated with the new immunosuppressive agent tasocitnib.			
	1700-1730	Volk <i>(Be</i>	Memory: Therapeutic Approaches To Memory-T Cells – Hans-Dieter erlin, Germany) es: Memory T-cells are a major challenge in transplantation. Tests for detecting allo-			
	1720 1900	memory.	New approaches on targeting memory T-cells.			

Stopping the Horse Out of the Barn – Can We Impact Late Pathways? – Roslyn Mannon (South Birmingham, AL) Objectives: To understand the mechanisms of fibrosis in the kidney. To understand the contribution of the immune response in fibrosis. Can new methods to stop or scarring/fibrosis.

1730-1800

1800-1900 ETHICS FORUM - Opting Out Strategies for Deceased Donor Organ Donation? - Mali III & IV

Professor Rafael Matesanz (Spain)

Chair: Aviva Goldberg and Linda Wright

Objectives: To discuss the Spanish system for deceased donor organ procurement, with particular reference to the opt-out model. To explore whether aspects of the Spanish system could be successfully implemented in a

Canadian system. To investigate what ethical issues may arise with these approaches.

1900-2000 LIBATIONS AMONG THE POSTERS (Odd numbers) - Kamichat/Sasseville/Joseph

2000-ON 

#### SATURDAY, MARCH 5 / LE SAMEDI 5 MARS 2011

0645-1000 **REGISTRATION – INSCRIPTION** - Foyer

0700-0745 SUNRISE SYMPOSIUM - Mali III & IV

Chair: David Landsberg

Living Donation in the US and Canada: Strategies and Strengths - Dorry Segev (Baltimore,

MD) and Jeffrey Zaltzman (Toronto, ON)

Objectives: To understand living kidney donor safety. To understand trends in kidney paired donation. To describe expansions of kidney paired donation. Compare and contrast Canadian experience with living kidney transplants

versus USA. Donor differences between Canada & the USA.

0700-ON SET-UP POSTERS (Even numbers) - Kamichat/Sasseville/Joseph

0700-1200 **EXHIBITS CONTINUE - Mali / & //** 

CST PLENARY SESSION III - FRONTIERS OF IMMUNOLOGY - Mali III & IV 0800-1200

Chair: Lee Anne Tibbles

0800-0830 Targeting Inflammation in Transplant – Tony Jevnikar (London, ON)

> Objectives: To understand the impact of cell death on various forms of graft injury and inflammation. To understand potential therapeutic interventions in ischemia reperfusion and

rejection injury.

0830-0915 Oral Basic Science Abstract Presentations (8 min. each)

> 0830 Prevention of Lung Ischemia Reperfusion Injury by Mesenchymal Stem Cells in a Mouse Model of Orthotropic Lung Transplantation - Shuhua Luo (London, ON)

(Abstract # 437)

Minimizing Donor Organ Immunogenicity in Kidney Transplantation Using siRNA -0840

Xuifen Zheng (London, ON) (Abstract # 411)

0900 Normothermic Acellular Ex Vivo Liver Perfusion (NEVLP) for the Storage, Assessment,

and Repair of Marginal Liver Grafts. - Markus U. Boehnert (Toronto, ON) (Abstract #

0910 Apoptotic Endothelial Cell Microenvironment, Through MFG-E8 Release, Reprograms

Macrophages Into Pro-Fibrotic Cells - Marie-Joëlle Brissette (Montréal, QC) (Abstract

# 392)

0915-0945 Understanding T Cell Regeneration In Human: A Bedside to Bench Approach

- Martin Guimond (Montréal, QC)

Objectives: To learn about mouse models of T-Cell regeneration in the setting of lymphopenia or following allogeneic stem cell transplantation and graft versus host disease. To discuss about

the role of dendritic cells in T cell regeneration.

0945-1015 REFRESHMENT BREAK - PAUSE SANTÉ - Mali I & II

1015-1200 CST PLENARY SESSION III - (Continued) - Mali III & IV

Chair: Carl Cardella

1015-1045 **Tregitopes As Tolerance Inducers - Nader Najafian (Boston, MA)** 

Objectives: What are Tregitopes. Role of Tregs in tolerance. Role of Tregitopes in tolerance.

1045-1130 Oral Basic Science Abstract Presentations (8 min. each)

> 1045 Mannose-Liposome Directed siRNA Silencing of CD40 to Prevent Cardiac Allograft

- Xusheng Zhang (London, ON) (Abstract # 478)

	l	1055	Alterations in CD4+FOXP3+ Regulatory T-Cell Diversity after Infant Heart				
		1105	Transplantation - Emsé Dijke <i>(Edmonton, AB)</i> (Abstract # 479)  Antibodies Against The LG3 Fragment Of Perlecan Are Novel Biomarkers Of Vascular  Antibodies Against Transplant Petiente, Mélaria Disudé <i>(Mantréal, OC)</i> (Abstract # 424)				
		1115	Injury In Renal Transplant Patients - Mélanie Dieudé (Montréal, QC) (Abstract # 424) CD4, CD8, Treg And Th17 Kinetics In Solid Organ Transplant Patients With CMV Infection - Moacyr Silva (Edmonton, AB) (Abstract # 462)				
	1130-1200	Regulation of Adaptive Immune Responses by Innate Immunity: Learning from Superbugs - Joaquim Madrenas (London, ON) Objectives: To review links between innate and adaptive immunity. To examine regulation of adaptive immune responses by innate immunity. To discuss potential therapeutic developments based on innate reception.					
0800-1400	CST ASSOCIATE MEMBERS FORUM - Soutana I & II						
	0800-0900						
	0910-0915		ne Address: Alison Drabble - Chair				
	0915-1000	Researc	ote Address: Collaborative Practice: Implications For Transplant ch, Education And Interprofessional Care - Dr. Carole Chatalalsingh, PhD sissauga, ON)				
	1000-1015		ch Presentation:: HCV Liver Recipients And Total Antioxidant Capacity Diet - Dr. Janet Madill, PhD RD (Toronto, ON)				
	1015-1030		ion of an Advanced Practice Nurse Collaborative Chronic Kidney Care or Renal Transplant Patients - Janice Bissonnette, RN-(EC)/NP, MScN, PhD ON)				
	1030-1045	Games	ch Presentation: Impact Of Participation In The World Transplant On Physical Fitness, Activity, Patterns And Quality Of Life: A Study Of ic Solid Organ Transplant Recipients - Robin Deliva, BScPT, MSc, o, ON)				
	1100-1130	Heart Ti	To The Heart Of The Matter: Distress And Impaired Quality Of Life In ransplant Recipients - Oliver Mauthner, RN MN PhD(C), Enza De Luca RN, arch Associates, PITH Project.				
	1130-1200	Abstrac	t Presentations				
		1130	Surfing for Health: The Development of a Transplant Website for Teens - Moria Korus, BA, RN, RSCN, (Toronto, ON) (Abstract # 425)				
		1145	The Beanstalk Program: The Developmentally Focused Care for the Young Transplant Child During Prolonged Hospitalization - Stephanie So, BScPT, (Toronto, ON) (Abstract # 444)				
	1200-1300 1300-1355	Researc	and Networking th 101: Workshop and Interactive Breakout Sessions ors: Robin Deliva, Janet Madill, Jennifer Harrison and Stacey Pollock				
	1355-1400	Closing	Remarks				
1200-1600	HEALTH CANADA WORKSHOP - Charivari-Sauteux-Corriveau						
1200 1000	1200-1215		ne Address - Dr. Duc Vu				
		Objective. and be av Health Ca organ saf	s: Have a better understanding of the regulatory monitoring of organ safety in Canada ware of its results to date. Be aware of the type of information that would facilitate anada's evaluation of suspected donor-derived adverse reactions. Identify what kind of Gety information they would like to obtain from Health Canada. Provide input on the best of m to establish an organ safety network.				
	1215-1300	Donor-c	derived Infections in Transplant Recipients - Dr. Atul Humar				
	1300-1330		ring the Safety of Organs for Transplantation in Canada; Where We v, Where We Want to Go - Dr. Duc Vu and Dr. Carole Légaré				
	1330-1345		ation by Health Canada's Inspectorate - (TBC)				
	1345-1430		n We Best Partner? - Group Discussion				
	1430-1445	Health I					
	1445-1530	-	oing an Organ Safety Network - Group Discussion				
	1530-1600	Reporti	ng on Breakout Sessions, Next Steps, Closing Remarks				
1200-1600	*******************************						

1600-1700 CST PLENARY SESSION IV - LEVELLING THE PLAYING FIELD - DEALING WITH

DISPARITIES IN THE CANADIAN SYSTEM - Mali III & IV

Chair: Véronique Phan

1600-1630 SCD, ECD, DCD - Donation disparities in Canada - Jagbir Gill (Vancouver, BC)

Objectives: To review practices relating to DCD & SCD transplantation in Canada. To compare

activity across regions in Canada.

1630-1700 A Growing Problem? Living Donation For Pediatric Recipients In Canada -

Tom Blydt-Hansen (Winnipeg, MB)

Objectives: Understand the changing role of living donation in children.

1700-1800 DEBATE – ORGANS SHOULD BE SHARED ACROSS CANADA - Mali III & IV

Chair: Greg Knoll

PRO - Peter Nickerson (Winnipeg, MB)

Objectives: Understand who is disadvantaged by only provincial organ allocation. Review mechanisms to create

solutions for patients. Discuss barriers to implementing solutions.

CON - Sandra Cockfield (Edmonton, AB)

Objectives: Review current barriers to national organ sharing. Discuss the adverse consequences to organ sharing.

Provide alternatives to national organ sharing.

1800-1830 CBS Report - Mali III & IV

1830-1900 CORR Report - Mali III & IV

1900-2000 LIBATIONS AMONG THE POSTERS (Odd numbers) - Kamichat/Sasseville/Joseph

1800-ON KIDS' EVENING - Sauteux - Corriveau

2000-ON ANNUAL DINNER AND AWARDS - Mali III & IV

This event is an accredited group learning activity as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and pending approval by the Canadian Association of General Surgeons.

La présente activité, en attente de l'approbation par l'Association canadienne des chirurgiens généraux, constitue une activité de formation collective agréée conformément à la définition précisée dans le programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada.

#### CST EXECUTIVE - 2010-2011 - BUREAU DE DIRECTION DE LA SCT

President, **Dr. Marcelo Cantarovich**Past President, **Dr. Lee Anne Tibbles**President Elect, **Dr. Tom Blydt-Hansen**Secretary Treasurer, **Dr. Shaf Keshavjee**Councillor **Dr. Steven Paraskevas**Councillor, **Dr. Atul Humar**Councillor, **Dr. David Grant** 

Councillor, Associate Member, Ms. Alison Drabble

2010 - 2011

# CST SCIENTIFIC PROGRAM COMMITTEE COMITÉ DU PROGRAMME SCIENTIFIQUE DE LA SCT

Dr. Steven Paraskevas, Chair Dr. John Gill, Co-Chair

Dr. Mark Cattral Dr. Colin Anderson Ms. Norine Heywood Dr. Atul Humar Dr. Michael Mengel Dr. Véronique Phan Dr. Tom Waddell Dr. Lori West